News

Tuesday, 14. August 2018 | Filed under Company News

Company News: Curetis Announces Financial Results for the First Six Months of 2018

Successful U.S. launch of Unyvero System and LRT Application Cartridge, with strong pipeline of sales opportunities

– Unyvero UTI Application Cartridge launched as CE-IVD product, 

BCU and HPN Application Cartridges approved in Singapore

– Commercial reach expanded to Latin America and Northern Africa

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2018, and provided a business update for 2018 year-to-date and its outlook for the future. 

Read more…

Tuesday, 14. August 2018 | Filed under Company News

Company News: Curetis Announces Change in Curetis USA Inc. Management

— Christopher M. Bernard resigns as President & CEO of Curetis USA Inc. effective August 31, 2018

— Chris D. Emery to succeed as President & CEO of Curetis USA Inc. effective September 1, 2018

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Christopher M. Bernard has informed the Company of his resignation as President and CEO of Curetis USA Inc. and as member of the Curetis N.V. Management Board, effective respectively August 31, 2018.

Read more…

Tuesday, 7. August 2018 | Filed under Company News

Company News: Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets

— New Unyvero distribution partnerships in Egypt, Mexico, and Uruguay

— Contractual commitments for 45 Unyvero Systems

Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced exclusive distribution partnerships in Egypt, Mexico, and Uruguay with Future Horizon Scientific, Quimica Valaner S.A. de C.V., and Biko S.A., respectively. The signing of these agreements follows a systematic qualification process conducted by Curetis, which focused on identifying distributors that are experienced in commercializing innovative products for international molecular diagnostics companies.

Read more…